[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

April 2017 - April 2015

Decade

Year

Issue

April 2017, Vol 3, No. 4, Pages 427-568

Viewpoint

Annual Meeting Highlights

Highlights in Head and Neck Cancer

Abstract Full Text
JAMA Oncol. 2017;3(4):441-442. doi:10.1001/jamaoncol.2016.3648

This Viewpoint highlights recent advances in the treatment of head and neck cancer reported at the 2016 ASCO meeting.

Personalized and Conscientious Medical ImagingTo Image or Not to Image

Abstract Full Text
JAMA Oncol. 2017;3(4):443-444. doi:10.1001/jamaoncol.2016.2220

This Viewpoint proposes ways to avoid excessive use of medical imaging to decrease the risk of secondary cancers caused by imaging-related radiation exposure.

Cancer Care Chronicles

When “Rocking the Boat” Saves a Life

Abstract Full Text
JAMA Oncol. 2017;3(4):445. doi:10.1001/jamaoncol.2016.3043
Editorial

Surveillance of Hepatocellular Carcinoma by Magnetic Resonance Imaging With Liver-Specific Contrast

Abstract Full Text
JAMA Oncol. 2017;3(4):446-447. doi:10.1001/jamaoncol.2016.3133

Universal Genetic Testing for Younger Patients With Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2017;3(4):448-449. doi:10.1001/jamaoncol.2016.5193

JAMA Oncology—The Year in Review, 2016

Abstract Full Text
free access
JAMA Oncol. 2017;3(4):450-451. doi:10.1001/jamaoncol.2016.7045
Original Investigation

MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma

Abstract Full Text
JAMA Oncol. 2017;3(4):456-463. doi:10.1001/jamaoncol.2016.3147

This clinical trial examines the hepatocellular carcinoma detection rate using ultrasonography compared with magnetic resonance imaging in patients with cirrhosis who are at high risk for hepatocellular carcinoma.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2017;3(4):464-471. doi:10.1001/jamaoncol.2016.5194

This cohort study examines the frequency and spectrum of cancer susceptibility gene mutations among patients with early-onset colorectal cancer.

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers A Secondary Analysis of 2 Randomized Clinical Trials

Abstract Full Text
JAMA Oncol. 2017;3(4):472-480. doi:10.1001/jamaoncol.2016.5469

This secondary analysis of 2 randomized clinical trials examines the association of DNA mismatch repair status and somatic gene mutations in the primary tumor of patients with stage III colon cancer treated with adjuvant chemotherapy.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell CancerA Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2017;3(4):483-491. doi:10.1001/jamaoncol.2016.5478

This secondary analysis of a randomized clinical trial examines whether a germline mutation in a microRNA-binding site in KRAS is a predictive biomarker of cetuximab response and altered immunity following radiotherapy and cisplatin treatment for head and neck squamous cell cancer.

Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant

Abstract Full Text
JAMA Oncol. 2017;3(4):493-500. doi:10.1001/jamaoncol.2016.5116

This multicenter study evaluated patients with hepatocellular carcinoma who underwent liver transplantation to develop and validate a recurrence prediction index.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell CancerThe ROPETAR Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2017;3(4):501-508. doi:10.1001/jamaoncol.2016.5202

This randomized clinical trial compares the effects of an 8-week rotating treatment schedule with pazopanib and everolimus vs continuous pazopanibon disease progression in patients with metastatic clear cell renal cell cancer.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast CancerEvidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab

Abstract Full Text
JAMA Oncol. 2017;3(4):509-515. doi:10.1001/jamaoncol.2016.5281

This cohort study investigates whether PI3K pathway–directed therapy is effective in the treatment of mesenchymal triple-negative breast cancer.

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior TherapySWOG S1115 Study Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2017;3(4):516-522. doi:10.1001/jamaoncol.2016.5383

This phase 2 randomized clinical trial compares selumetinib and MK-2206 vs modified FOLFOX chemotherapy in patients with metastatic pancreatic cancer for whom gemcitabine-based therapy had failed.

Invited Commentary

Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal CancerWhat Happens at Relapse?

Abstract Full Text
JAMA Oncol. 2017;3(4):481-482. doi:10.1001/jamaoncol.2016.5463

The KRAS Variant as a Predictive Biomarker of Cetuximab Response in Head and Neck Cancer

Abstract Full Text
JAMA Oncol. 2017;3(4):491-492. doi:10.1001/jamaoncol.2016.5686
Special Communication

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015A Systematic Analysis for the Global Burden of Disease Study

Abstract Full Text
free access
JAMA Oncol. 2017;3(4):524-548. doi:10.1001/jamaoncol.2016.5688

Using the methodology and data sources of the Global Burden of Disease study, this systematic analysis estimates mortality, incidence, years lived with disability, years of life lost, and disability-adjusted life-years for 32 cancers in 195 countries and territories from 1990 to 2015.

Review

Axillary Nodal Management Following Neoadjuvant ChemotherapyA Review

Abstract Full Text
has active quiz
JAMA Oncol. 2017;3(4):549-555. doi:10.1001/jamaoncol.2016.4163

This review discusses the controversies and unanswered questions regarding axillary management in patients receiving neoadjuvant chemotherapy for breast cancer.

JAMA Oncology Clinical Challenge

Large Epigastric Cystic Lesion in a Pregnant Woman

Abstract Full Text
JAMA Oncol. 2017;3(4):557-558. doi:10.1001/jamaoncol.2016.5846

A pregnant woman in her 20s presented with abdominal pain and a cystic mass that appeared on scanning results to originate from the body of the pancreas. What is your diagnosis?

Research Letter

Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China

Abstract Full Text
JAMA Oncol. 2017;3(4):562-564. doi:10.1001/jamaoncol.2016.5487

This study examines the association of malignant mesothelioma with exposure to asbestos among individuals in Eastern China.

Comment & Response

Advances in the Decision to Image or Not to Image

Abstract Full Text
JAMA Oncol. 2017;3(4):564-565. doi:10.1001/jamaoncol.2016.5061

Advances in the Decision to Image or Not to Image—Reply

Abstract Full Text
JAMA Oncol. 2017;3(4):565. doi:10.1001/jamaoncol.2016.4849

Clinical Diagnosis of Mental Disorders Before Cancer Diagnosis

Abstract Full Text
JAMA Oncol. 2017;3(4):565-566. doi:10.1001/jamaoncol.2016.5293

Clinical Diagnosis of Mental Disorders Before Cancer Diagnosis—Reply

Abstract Full Text
JAMA Oncol. 2017;3(4):566. doi:10.1001/jamaoncol.2016.5279

Lymphoma and Pregnancy

Abstract Full Text
JAMA Oncol. 2017;3(4):566-567. doi:10.1001/jamaoncol.2016.5290

Lymphoma and Pregnancy—Reply

Abstract Full Text
JAMA Oncol. 2017;3(4):567-568. doi:10.1001/jamaoncol.2016.4848
Correction

Clarification of Conflict of Interest Disclosure

Abstract Full Text
free access
JAMA Oncol. 2017;3(4):568. doi:10.1001/jamaoncol.2017.0067
Peer Reviewers List

JAMA Oncology Peer Reviewers in 2016

Abstract Full Text
free access online only
JAMA Oncol. 2017;3(4):e170110. doi:10.1001/jamaoncol.2017.0110
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(4):430. doi:10.1001/jamaoncol.2016.1684
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(4):427. doi:10.1001/jamaoncol.2016.1683
×